Beclomethasone dipropionate : efficacy and safety of the administration by nebulization.
The advent of inhaled corticosteroids (ICS) brought a revolution in the management of asthma, representing now the cornerstone in this pathological condition treatment. Indeed, these drugs have clearly shown to possess a high degree of both efficacy and safety. Beclomethasone dipropionate (BDP) is the first molecule tested in the early 1970s. When administered via nebulizers or pressurized metered-dose inhalers (pMDI), BDP was found to be effective in reducing the symptoms frequency and severity in asthmatic patients, even in those previously treated with low-dose oral corticosteroids. The drug was thus produced to be administered by nebulization or via pMDI. Nebulizers are a practical and efficient tool for administering inhaled drugs in patients of all degree of severity and belonging to all ages, but are especially useful for those unable to utilize other inhaler devices correctly. BDP aerosolization, when generated by modern pneumatic nebulizers, can deliver particles with a mass median aerodynamic diameter (MMAD) value of 2.9-3.7 µm. This ability allows the deposition of the drug in small caliber airways, and considerably reduces the amount of drug deposited in the oropharynx, thus improving this molecule pharmacokinetics. This review aims to analyze the factors influencing the efficacy and safety of ICS, evaluating in detail the characteristics of BDP administered by nebulization.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:113 |
---|---|
Enthalten in: |
Recenti progressi in medicina - 113(2022), 12 vom: 05. Dez., Seite 1-12 |
Sprache: |
Italienisch |
---|
Weiterer Titel: |
Il beclometasone dipropionato: efficacia e sicurezza della somministrazione mediante nebulizzazione |
---|
Beteiligte Personen: |
Tosca, Mariangela [VerfasserIn] |
---|
Links: |
---|
Themen: |
Adrenal Cortex Hormones |
---|
Anmerkungen: |
Date Completed 28.12.2022 Date Revised 30.01.2023 published: Print Citation Status MEDLINE |
---|
doi: |
10.1701/3937.39206 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM350849668 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM350849668 | ||
003 | DE-627 | ||
005 | 20231226045925.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||ita c | ||
024 | 7 | |a 10.1701/3937.39206 |2 doi | |
028 | 5 | 2 | |a pubmed24n1169.xml |
035 | |a (DE-627)NLM350849668 | ||
035 | |a (NLM)36573485 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a ita | ||
100 | 1 | |a Tosca, Mariangela |e verfasserin |4 aut | |
245 | 1 | 0 | |a Beclomethasone dipropionate |b efficacy and safety of the administration by nebulization. |
246 | 3 | 3 | |a Il beclometasone dipropionato: efficacia e sicurezza della somministrazione mediante nebulizzazione |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 28.12.2022 | ||
500 | |a Date Revised 30.01.2023 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a The advent of inhaled corticosteroids (ICS) brought a revolution in the management of asthma, representing now the cornerstone in this pathological condition treatment. Indeed, these drugs have clearly shown to possess a high degree of both efficacy and safety. Beclomethasone dipropionate (BDP) is the first molecule tested in the early 1970s. When administered via nebulizers or pressurized metered-dose inhalers (pMDI), BDP was found to be effective in reducing the symptoms frequency and severity in asthmatic patients, even in those previously treated with low-dose oral corticosteroids. The drug was thus produced to be administered by nebulization or via pMDI. Nebulizers are a practical and efficient tool for administering inhaled drugs in patients of all degree of severity and belonging to all ages, but are especially useful for those unable to utilize other inhaler devices correctly. BDP aerosolization, when generated by modern pneumatic nebulizers, can deliver particles with a mass median aerodynamic diameter (MMAD) value of 2.9-3.7 µm. This ability allows the deposition of the drug in small caliber airways, and considerably reduces the amount of drug deposited in the oropharynx, thus improving this molecule pharmacokinetics. This review aims to analyze the factors influencing the efficacy and safety of ICS, evaluating in detail the characteristics of BDP administered by nebulization | ||
650 | 4 | |a Review | |
650 | 4 | |a English Abstract | |
650 | 4 | |a Journal Article | |
650 | 7 | |a Beclomethasone |2 NLM | |
650 | 7 | |a KGZ1SLC28Z |2 NLM | |
650 | 7 | |a Anti-Asthmatic Agents |2 NLM | |
650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
700 | 1 | |a Rossi, Giovanni A |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Recenti progressi in medicina |d 1948 |g 113(2022), 12 vom: 05. Dez., Seite 1-12 |w (DE-627)NLM000023124 |x 2038-1840 |7 nnns |
773 | 1 | 8 | |g volume:113 |g year:2022 |g number:12 |g day:05 |g month:12 |g pages:1-12 |
856 | 4 | 0 | |u http://dx.doi.org/10.1701/3937.39206 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 113 |j 2022 |e 12 |b 05 |c 12 |h 1-12 |